Role of activin A in carbon tetrachloride-induced acute liver injury

Dong-Hui Wang, Yi-Nan Wang, Jing-Yan Ge, Hai-Yan Liu, Hong-Jun Zhang, Yan Qi, Zhong-Hui Liu, Xue-Ling Cui

Dong-Hui Wang, Jing-Yan Ge, Han-Yan Liu, Yan Q, Zhong-Hui Liu, Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun 130021, Jilin Province, China

Yi-Nan Wang, Translational Medical Research Institute, First Hospital of Jilin University, Changchun 130061, Jilin Province, China

Hong-Jun Zhang, Department of Immunology, Mudanjiang Medical University, Mudanjiang 157011, Heilongjiang Province, China

Xue-Ling Cui, Department of Genetics, Norman Bethune College of Medicine, Jilin University, Changchun 130021, Jilin Province, China

Author contributions: Wang DH and Wang YN contributed equally to this work; Wang DH, Ge JY, Liu HY and Qi Y participated in the animals experiments, collected data and performed the statistical calculations; Cui XL participated in the animals experiments and drafting the manuscript; Wang YN, Zhang HJ and Liu ZH participated in the design of the study, performed literature searches and drafted the manuscript; all authors read and approved the final manuscript.

Supported by The Natural Science Foundation of China, Grants No. 30801005, No. 81273199 and No. 81270513; and the Project of Science and Development of Jilin Province (to Liu ZH)

Correspondence to: Dr. Xue-Ling Cui, Department of Genetics, Norman Bethune College of Medicine, Jilin University, 126 Xinmin Street, Changchun 130021, Jilin Province, China. cxl@jlu.edu.cn

Telephone: +86-431-85619476 Fax: +86-431-85639362

Received: February 16, 2013 Revised: April 12, 2013

Accepted: May 8, 2013

Published online: June 28, 2013

Abstract

AIM: To investigate the expression and role of activin A in a mouse model of acute chemical liver injury.

METHODS: Acute liver injury in C57BL/6 male mice was induced by intraperitoneal injection with carbon tetrachloride (CCl₄) (0.5 mL/kg, body weight) dissolved in olive oil (1:19 v/v). Mice were sacrificed 1, 3, 5 and 7 d after the treatment. The levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum were examined and pathological changes of liver observed by hematoxylin and eosin staining to evaluate the liver injury. Activin A protein levels in serum and hepatic tissue homogenate of mice were detected by enzyme-linked immunosorbent assay, and the expression pattern of activin A protein in livers of mice was examined by immunohistochemistry. Activin type II A receptor (ActR II A) and Smad3 expressions in the liver were analyzed by real-time quantitative reverse transcription-polymerase chain reaction. In order to further investigate the role of activin A, we also utilized activin A blocking experiment by anti-activin A antibody (500 μg/kg, body weight) injection into mouse tail vein.

RESULTS: In CCl₄-treated mice, serum ALT and AST levels were significantly increased, compared with that in control mice (P < 0.01). Furthermore, the serious necrosis was observed around hepatic portal areas in CCl₄-treated mice. Simultaneously, activin A levels in serum and hepatic tissue homogenate of mice treated with CCl₄ for 1, 3 and 5 d increased significantly, compared with that in control mice (P < 0.01). Activin A protein expression in hepatocytes not within the necrotic area was also upregulated in mice following CCl₄ treatment. Not only activin A, but also ActR II A and activin signaling molecule Smad3 mRNA expressions in injury liver induced by CCl₄ were significantly higher than that in control liver. In addition, levels of serum ALT and AST in CCl₄-treated mice were significantly decreased by injection of anti-activin A antibody to block endogenous activin A action, compared with that in CCl₄-treated mice by injection of immunoglobulin G instead of anti-activin A antibody (P < 0.01), and the severity of liver injury was also reduced remarkably.

CONCLUSION: These data show that activin A is involved in CCl₄-induced acute liver injury. Blocking activin A actions may be a therapeutic approach for acute liver injury.

© 2013 Baishideng. All rights reserved.
Key words: Liver injury; Carbon tetrachloride; Activin A; Immunohistochemistry

Core tip: The objective of this study was to investigate the expression and role of activin A in acute liver injury. A carbon tetrachloride (CCl₄)-induced acute liver injury mouse model was used. Liver injury effects were examined by measuring alanine aminotransferase and aspartate aminotransferase levels in serum and liver pathological changes. Activin A protein expression levels were detected by enzyme-linked immunosorbent assay and immunohistochemistry. Activin type II A receptor and Smad3 expressions in liver were analyzed by real-time quantitative reverse transcription-polymerase chain reaction. We found that activin A is involved in CCl₄-induced acute liver injury, suggesting activin A could be a potential therapeutic option for acute liver injury diseases.

INTRODUCTION

Activin A, a member of the transforming growth factor-β (TGF-β) superfamily, has a wide range of biological roles.[1-3] It is distributed widely in various tissues and produced by numerous cells including macrophages, T-helper 2 cells and hepatocytes.[4-6] It plays important roles in regulation of pituitary hormone release, neuron survival, hematopoiesis and the early development of embryos.[7-10] The expression of activin A is closely related to liver diseases, and abnormal expression of activin A and its signal proteins are found during the development of virus hepatitis, hepatic fibrosis, liver cancer and other diseases.[11-14] Activin A affects the function of hepatocytes by inhibiting DNA synthesis while stimulating the synthesis of the extracellular matrix of hepatic stellate cells, which can result in the hepatic fibrosis.[12,13] The liver is an important metabolic organ in the body, and can be injured by various factors, which include viral infection, trauma, and chemical reagents. Carbon tetrachloride (CCl₄)-induced liver injury is a classic model of chemical liver injury in mice.[15] Activin A expression increased significantly in CCl₄-induced chronic liver injury in mice, marking it as an important factor in liver fibrosis development.[16] However, it is still unclear whether activin A is involved in the process of CCl₄-induced acute chemical liver injury.

In the present study, the expression and role of activin A were investigated in CCl₄-induced acute chemical liver injury in mice. Further, the role of activin A in the process of acute liver injury was confirmed by in vitro blockade of activin A action.

MATERIALS AND METHODS

Reagents

CCl₄ was purchased from Beijing Chemical Factory (batch number 20050106). Olive oil was obtained from Beijing Kelipie Tsui olive oil Development Centers. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) assay kit was provided by NJBI (Nanjing, China). Anti-activin A antibody was obtained from Sigma Company. Trizol reagent was provided by Invitrogen Corporation. SYBR fluorescence quantitative reverse transcription-polymerase chain reaction (PCR) kit was purchased from Takara Company.

Animals

C57BL/6 male mice were provided by Animal Center of Jilin University (Changchun, China). All animal experiments were performed following an institutionally approved protocol in accordance with the Jilin University Guide for the care and use of laboratory animals.

Preparation of CCl₄-induced acute liver injury mouse model

C57BL/6 mice were randomly divided into the olive oil control group and the CCl₄ group (n = 24). In the control group, mice were treated with olive oil (10 mL/kg) by intraperitoneal injection; in the CCl₄ group, mice were injected intraperitoneally with CCl₄ (0.5 mL/kg) + olive oil (9.5 mL/kg) (1:19 v/v). Mice were executed 1, 3, 5 and 7 d after the treatment, serum was collected for the determination of transaminases and activin A levels, and hepatic tissues were obtained for pathological examination and immunohistochemical staining.

Determination of serum transaminases ALT and AST

The serum transaminases ALT and AST levels were detected by assay kit according to the manufacturer’s protocol (NJBI, Nanjing, China). Briefly, 25 μL AST or ALT substrates and 5 μL serum were added into one well of polystyrene microtiter plates at 37 °C for 30 min. And then 25 μL of 2,4-dinitrophenylhydrazine was added in to all wells at 37 °C for 30 min. Finally, 250 μL of 0.4 mol/L sodium hydroxide was added to stop the reactions at room temperature for 15 min, and the absorbance at 510 nm in each well was measured with an enzyme-linked immunosorbent assay (ELISA) reader (BioRad Laboratories, Hercules, CA, United States). The levels of AST or ALT are expressed in U/L.

Pathological examination

The right lobe of each mouse liver was collected, fixed with 40 g/L paraformaldehyde for 24 h, embedded in paraffin, and sliced into a thickness of 3–4 μm. The sections were deparaffinized and pathological liver change were examined by hematoxylin and eosin (HE) staining.

Detection of activin A levels

To prepare the mouse hepatic tissue homogenate, 50 mg mouse liver was added to 1 mL lysis buffer (1% Triton 3803

June 28, 2013 | Volume 19 | Issue 24 | WJG | www.wjgnet.com
activin A receptor.

Real-time quantitative reverse transcription-PCR
Total hepatic tissue RNA was extracted using the Trizol reagent according to the manufacturer's protocol (Invitrogen), and then activin βA, Activin type II A receptor (ActRIIA) and Smad3 mRNA expressions were examined by SYBR real-time-PCR kit using a ABI PRISM 7700 sequence detection system (Perkin-Elmer Applied Biosystems) in a two-stage, single-tube reaction. The following reaction conditions were used: stage one, 95 °C, 10 s for 1 cycle; stage two, 95 °C, 5 s and 60 °C, 31 s for 40 cycles, collecting fluorescence in this phase; stage three, 95 °C, 15 s, 60 °C 1 min, 95 °C 15 s for 1 cycle. Primers were synthesized by BECL (Shanghai, China), and the sequences are shown in Table 1. The reverse transcription (RT)-PCR products were quantitatively analyzed according to a standard cDNA calibration curve[17].

Immunohistochemical staining
The right lobe of the liver was fixed by 40 g/L paraformaldehyde for 24 h, embedded in paraffin, and then sliced into a thickness of 3-4 μm. The sections were deparaffinized, and 3% hydrogen peroxide (H2O2)-methanol was used to block endogenous peroxidase at room temperature for 30 min. Two percent of bovine serum albumin in 0.01 mol/L phosphate-buffered saline (PBS) was used to block nonspecific reactivity by a preincubation of section for 30 min. The sections were then incubated in anti-activin A antibody (1:400) at 4 °C overnight. The sections were washed with PBS, bound antibodies were detected with SP1 kit (ZSJQ, Beijing, China) and immunoreactive products were visualized in 0.05% diaminobenzidine and 0.03% H2O2. The sections were counterstained with hematoxylin, dehydrated, cleared, counted and observed under an Olympus microscope (BX51). In control staining, the sections were incubated with normal mouse immunoglobulin G (IgG) instead of anti-activin A antibody[18].

Blocking experiment
C57BL/6 mice adaptive feeding for 7 d were randomly divided into four groups (n = 12). The IgG control group (IgG Cont), in which each mouse was injected intraperitoneally with olive oil (10 mL/kg), 2 h later, injected by tail vein with normal IgG (500 μg/kg); the antibody control group (Anti-A Cont), in which each mouse was injected intraperitoneally with saline (0.5 mL/kg) + olive oil (9.5 mL/kg), 2 h later, injected by tail vein with anti-activin A antibody (500 μg/kg); the CCl4 group (IgG + CCl4), in which each mouse was injected intraperitoneally with CCl4 (0.5 mL/kg) + olive oil (9.5 mL/kg), 2 h later, injected by tail vein with IgG (500 μg/kg); the antibody plus CCl4 group (Anti-A + CCl4), in which each mouse was injected intraperitoneally with CCl4 (0.5 mL/kg) + olive oil (9.5 mL/kg), 2 h later, injected by tail vein with anti-activin A antibody (500 μg/kg). Sera and livers of these mice were collected 3 d after CCl4 injection for determination of serum ALT and AST levels and pathological examination of livers.

Statistical analysis
The statistical software SPSS 10.0 was used to analyze all data. P < 0.05 was considered statistically significant.

RESULTS
The establishment of the acute liver injury mouse model
Change of serum transaminases ALT and AST levels is an important indicator of liver injury. Our results revealed that serum ALT and AST levels were significantly elevated on days 1, 3, 5 and 7 after the administration of CCl4, compared with that in control group, P < 0.01 (Figure 1A). Furthermore, lobular architecture in the control mouse liver was clear and the hepatic cells arranged in neat rows by HE staining. In mouse liver 1 d following CCl4 treatment, there were round necrotic lesions around the hepatic lobule portal area, and 3 d after CCl4 treatment, there was inflammatory cell infiltration in the hepatic lobule portal area (Figure 1B).

Increase of activin A levels in mice treated with CCl4
Activin A levels in serum and hepatic homogenates of experimental mice were determined by ELISA. The results showed that activin A levels increased significantly in serum and hepatic homogenate from CCl4-induced acute liver injury mice for 1, 3 and 5 d, compared with that in control group, P < 0.01 (Figure 2). These levels peaked on days 1 and 3, and returned to normal levels by day 7.

Elevation of activin A protein expression in liver of mice treated with CCl4
To explore the reason for increased activin A levels in the serum of CCl4-treated experimental mice and the

Table 1 Primer sequences for polymerase chain reaction

| Genes | Primers | Sequences | Product size (bp) |
|-------|---------|-----------|------------------|
| GAPDH Sense | 5'-GATTGTGCCATCAACGACC-3' | 371 |
| ActR II A Sense | 5'-ATTGGCCAGCATCCATCTCTTG-3' | 514 |
| Smad3 Sense | 5'-GAGAGGAGTGAACTGTTGCT-3' | 296 |
| ActR II A Antisense | 5'-ATGACTGTTGAGTGGAAGG-3' | 241 |

GAPDH: Glycerinaldehyde-3-phosphate dehydrogenase; ActR II A: Activin type II A receptor.

X-100, pH 7.5, 50 mmol/L Tris-HCl, 150 mmol/L NaCl, 2 mmol/L ethylenediaminetetraacetic acid, 2 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L sodium fluoride, 4 μg/mL leupeptin, 1 μg/mL aprotinin. The lysate was centrifuged for 30 min at 12000 rpm at 4 °C and the supernatant was harvested.

To explore the reason for increased activin A levels in the serum of CCl4-treated experimental mice and the

and observed under an Olympus microscope (BX51). In control staining, the sections were incubated with normal mouse immunoglobulin G (IgG) instead of anti-activin A antibody[18].

Blocking experiment
C57BL/6 mice adaptive feeding for 7 d were randomly divided into four groups (n = 12). The IgG control group (IgG Cont), in which each mouse was injected intraperitoneally with olive oil (10 mL/kg), 2 h later, injected by tail vein with normal IgG (500 μg/kg); the antibody control group (Anti-A Cont), in which each mouse was injected intraperitoneally with saline (0.5 mL/kg) + olive oil (9.5 mL/kg), 2 h later, injected by tail vein with anti-activin A antibody (500 μg/kg); the CCl4 group (IgG + CCl4), in which each mouse was injected intraperitoneally with CCl4 (0.5 mL/kg) + olive oil (9.5 mL/kg), 2 h later, injected by tail vein with IgG (500 μg/kg); the antibody plus CCl4 group (Anti-A + CCl4), in which each mouse was injected intraperitoneally with CCl4 (0.5 mL/kg) + olive oil (9.5 mL/kg), 2 h later, injected by tail vein with anti-activin A antibody (500 μg/kg). Sera and livers of these mice were collected 3 d after CCl4 injection for determination of serum ALT and AST levels and pathological examination of livers.

Statistical analysis
The statistical software SPSS 10.0 was used to analyze all data. P < 0.05 was considered statistically significant.

RESULTS
The establishment of the acute liver injury mouse model
Change of serum transaminases ALT and AST levels is an important indicator of liver injury. Our results revealed that serum ALT and AST levels were significantly elevated on days 1, 3, 5 and 7 after the administration of CCl4, compared with that in control group, P < 0.01 (Figure 1A). Furthermore, lobular architecture in the control mouse liver was clear and the hepatic cells arranged in neat rows by HE staining. In mouse liver 1 d following CCl4 treatment, there were round necrotic lesions around the hepatic lobule portal area, and 3 d after CCl4 treatment, there was inflammatory cell infiltration in the hepatic lobule portal area (Figure 1B).

Increase of activin A levels in mice treated with CCl4
Activin A levels in serum and hepatic homogenates of experimental mice were determined by ELISA. The results showed that activin A levels increased significantly in serum and hepatic homogenate from CCl4-induced acute liver injury mice for 1, 3 and 5 d, compared with that in control group, P < 0.01 (Figure 2). These levels peaked on days 1 and 3, and returned to normal levels by day 7.

Elevation of activin A protein expression in liver of mice treated with CCl4
To explore the reason for increased activin A levels in the serum of CCl4-treated experimental mice and the
Figure 1 Examination of serum alanine aminotransferase and aspartate aminotransferase levels and pathological changes of liver in carbon tetrachloride-treated mice. A: Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were detected by enzyme-linked immunosorbent assay in olive oil control mouse and carbon tetrachloride (CCl$_4$)-treated mouse. B: Pathological change of liver was analyzed by hematoxylin and eosin staining. Arrows represent lesion area (magnification, × 100).

Figure 2 Detection of levels of activin A in serum and hepatic homogenates of mouse treated with carbon tetrachloride by enzyme-linked immunosorbent assay. CCl$_4$: Carbon tetrachloride. $^{b}P < 0.01$ vs control.
expression pattern of activin A in acute liver injury, the expression of activin A protein was examined by immunohistochemical staining. The results revealed that activin A protein expression was detectable in the livers of olive oil-treated mice and in injured livers from CCl₄-treated mice. In addition, activin A protein expression in hepatocytes with non-necrotic area was up-regulated on days 1 and 3 after CCl₄ treatment (Figure 3).

Figure 3 Expression of activin A protein in liver of mouse assessed by immunohistochemical staining. A, B: Activin A expression was examined by using anti-activin A antibody in the same liver tissues on day 1 after olive oil treatment; C, D: Activin A expression was examined by using anti-activin A antibody in the same liver tissues on day 1 after carbon tetrachloride (CCl₄) treatment; E, F: Activin A expression was examined by using anti-activin A antibody in the same liver tissues on day 3 after CCl₄ treatment; G, H: The procedural background control staining was represented by using normal mouse immunoglobulin G instead of anti-activin A antibody in livers of olive oil-treated and CCl₄-treated mice. Red arrows represent lesion area and black arrows represent positive staining for activin A. A, C, E: Magnification × 100; B, D, F, G, H: Magnification × 200.
Activin A is a dimeric glycoprotein formed by two βA subunits. To further investigate activin and its signal molecule expression in liver injury, activin βA, ActRIIA and Smad3 mRNA expressions were examined by real-time quantitative RT-PCR. The results showed that not only activin βA mRNA, but also ActRIIA and intracellular signal protein Smad3 mRNA expressions were significantly increased in livers from CCl₄-treated mice when compared with that in control group, P < 0.01 (Figure 4).

Protective effect of anti-activin A antibody on CCl₄-treated mouse liver

In order to further confirm that activin A was involved in acute liver injury, pathological changes of livers in CCl₄-treated mice were examined after injection of an anti-activin A antibody to block endogenous activin action. The results revealed that serum ALT and AST levels in mice treated with anti-activin A + CCl₄ were significantly lower than that in IgG + CCl₄ control mice (Figure 5A, P < 0.01). Furthermore, the results showed that the necrotic severity around the hepatic lobule portal area in mice treated with anti-activin A + CCl₄ was remarkably reduced compared with that in IgG + CCl₄ control mice (Figure 5B).

DISCUSSION

Biologic activity of activin

Activin A as a multifunctional factor plays an important role in acute phase immune response, and its expression levels are increased in several inflammatory diseases such as sepsisemia, inflammatory bowel disease, and rheumatoid arthritis[19-22]. Recent studies have reported that activin A is closely related to the liver diseases hepatitis and hepatic fibrosis[13,14,16]. Activin receptors belong to serine/threonine kinase receptors of the TGF-β superfamily, are divided into ActRI and ActRII. Activin binds directly to the type II receptor on the cell membrane, and then recruits the type I receptor[23,24]. Further, the activated type I receptor propagates the signal through a cascade reaction elicited by downstream Smad proteins into the nucleus to activate target genes[25,26].

Damage effects of CCl₄ on the liver

CCl₄ is a chemical reagent that induces mouse liver injury, a classic chemical model for studying liver injury. The principle of injury is that in the function of cytochrome P450, CCl₄ generates chloromethyl free radicals (-CCl₃), which enable the peroxidation of the membrane lipids on the liver cell membrane or subcellular structure causing the rise of membrane permeability that results in the release of large number of ALT in the cytoplasm into blood. Another possibility is covalent binding of -CCl₃ and hepatic microsomal lipids and proteins that damage the integrity of the structure and function of hepatic cell membranes[27-29]. Additionally, various factors can further aggravate CCl₄-induced liver injury in mice, such as the increase of activin A expression in chronic liver injury[16].

Role of activin in liver injury

Abnormal expression of activin A is related to a variety of liver diseases, and activin A can directly induce hepatocyte apoptosis and inhibit hepatocyte proliferation and DNA synthesis[21,25]. To investigate whether activin A is involved in acute chemical liver injury, C57BL/6 mice were injected with CCl₄ through peritoneal cavity to establish acute liver injury model. The results showed that serum ALT and AST increased, and serious necrosis of hepatic tissue was observed by HE staining in CCl₄-treated mice. Simultaneously, activin A levels increased significantly in serum and hepatic tissue homogenate of mice treated with CCl₄. By immunohistochemical staining, the elevated expression of activin A protein was also observed in the injured livers of CCl₄-treated mice. Since CCl₄ induced necrotic death of hepatocytes in large area, which necrotic hepatocytes could not release cytokines, but the decomposition product of necrotic tissues as inflammatory stimulator could induce hepatocytes activation to secrete activin A. Thus, activin A protein was expressed in hepatocytes around the necrotic area and the

Figure 4 Assay of mRNA expressions of activin βA and activin signal molecules in liver of mouse by real-time quantitative reverse transcription-polymerase chain reaction. The mRNA levels in olive oil control group (Cont) were adjusted to 100%. All values (mean ± SD) were expressed as % of that in control. *P < 0.05, **P < 0.01 vs control.
activated hepatocytes have larger clear nuclei. In addition, the real-time quantitative RT-PCR results revealed that in CCl4-treated mice, activin A, ActRII A and intracellular activin signal protein Smad3 mRNA expressions significantly increased. In order to further confirm the role of activin A in CCl4-induced liver injury, pathological changes of livers in CCl4-treated mice were examined after injection with anti-activin A antibody to block endogenous activin action. These results revealed that activin A might participate in the process of CCl4-induced liver injury via inhibiting proliferation and DNA synthesis of hepatocytes to aggravate the CCl4-induced liver injury, and blockade of activin A actions by anti-activin A antibody could significantly reduce the levels of serum transaminases and the necrosis severity of hepatic tissue in CCl4-treated mice.

In summary, these data suggested that the activin A-ActR II A-Smad signal transduction cascade was induced in CCl4-treated mice. Further, activin A was involved in the process of CCl4-induced acute chemical liver injury of mice in an autocrine/paracrine manner. Activin A may be a potential therapeutic target for acute liver injury disease.

**COMMENTS**

**Background**

Activin A is an important mediator of liver cells, not only in proliferation of hepatocytes, but also in activation of hepatic stellate cells, secretion of liver extracellular matrix, as well as the formation and development of liver injury.

**Research frontiers**

Previous studies have demonstrated the effect of activin A on CCl4-induced chronic liver injury in mice, however, the effect and mechanism of activin A on CCl4-induced acute liver injury remains undefined.

**Innovations and breakthroughs**

New therapies that aim to block biological role of activin A in liver injury diseases are being actively explored and evaluated. Authors believe this study to be the first to explore the effect of activin A on acute liver injury.

**Applications**

The findings that block the biological action of activin A may be clinically relevant to potential liver injury therapeutics.

**Terminology**

Activin is a multifunctional factor of transforming growth factor-β superfamily. There are three types of activins formed by homo- or hetero-dimerization of two inhibin subunits (IA and IB), activin A (IAIA), activin B (IBIB) and activin AB (IAIB). Activin A is an important mediator in CCl4-induced acute liver injury in mice, and blockade of biological action of activin A may be a potential therapeutic for acute liver injury diseases.

**Peer review**

This is a good descriptive study in which authors analyze the role of activin A in carbon tetrachloride-induced acute liver injury in mouse. The results are interesting and suggest that activin A is involved in the process of CCl4-induced acute liver injury in an autocrine/paracrine manner. Further, the authors show that an antibody-mediated blockade of activin A biological action may provide insights into potential therapeutics.

**REFERENCES**

1. Kingsley DM. The TGF-beta superfamily: new members,
new receptors, and new genetic tests of function in different organisms. *Genes Dev* 1994; 8: 133-146 [PMID: 8299934]

2 Chen YG, Lui HM, Lin SL, Lee JM, Ying SY. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. *Exp Biol Med* (Maywood) 2002; 227: 75-87 [PMID: 11815670]

3 Phillips DJ, de Krefter DM, Hedger MP. Activin and related proteins in inflammation. *Cytokine Growth Factor Rev* 2009; 20: 153-164 [PMID: 19261538]

4 Wang SY, Tai GX, Zhang PY, Mu DP, Zhang XJ, Liu ZH. Inhibitory effect of activin A on activation of lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells. *Cytokine* 2008; 42: 85-91 [PMID: 18321725 DOI: 10.1016/j.cyto.2008.01.010]

5 Ogawa K, Funaba M, Chen Y, Tsujimoto M. Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. *J Immunol* 2006; 177: 6787-6794 [PMID: 17082592]

6 Gold EJ, Zhang X, Wheatley AM, Mellor SL, Cranfield M, Risbridger GP, Groome NP, Fleming JS. beta-A- and beta-C-activin, follistatin, activin receptor mRNA and beta-activin peptide expression during rat liver regeneration. *J Mol Endocrinol* 2005; 34: 505-515 [PMID: 15821113]

7 Mendis SH, Meachem SJ, Sarraj MA, Loveland KL. Activin A balances Sertoli and germ cell proliferation in the fetal mouse testis. *Biol Reprod* 2011; 84: 379-391 [PMID: 20926807 DOI: 10.1095/biолreprod.110.086231]

8 Thomsen G, Woold T, Whitanek M, Sokol S, Vaughan J, Vale W, Melton DA. Activins are expressed early in Xenopus embryogenesis and can induce axial mesoderm and anterior structures. *Cell* 1990; 63: 485-493 [PMID: 2225062]

9 Fang L, Wang YN, Cui X, Fang SY, Ge JO, Sun Y, Liu ZH. The role and mechanism of action of activin A in neurite outgrowth of chicken embryonic dorsal root ganglia. *J Cell Sci* 2012; 125: 1500-1507 [PMID: 22275431 DOI: 10.1242/jcs.094151]

10 Liu ZH, Shintani Y, Sakamoto Y, Harada K, Zhang CY, Fujinaka Y, Abe M, Goto T, Saito S. Effects of LHRH, FSH and activin A on follistatin secretion from cultured rat anterior pituitary cells. *Endocr J* 1996; 43: 321-327 [PMID: 8886627]

11 Werner S, Alzheimer C. Roles of activin in tissue repair, fibrosis, and inflammatory disease. *Cytokine Growth Factor Rev* 2006; 17: 157-171 [PMID: 16481210]

12 Date M, Matsuzaki K, Matsushita M, Tahashi Y, Sakitani K, Inoue K. Differential regulation of activin A for hepatocyte growth and fibronectin synthesis in rat liver injury. *J Hepatol* 2000; 32: 251-260 [PMID: 10707865]

13 Zhang HJ, Tai GX, Zhou J, Ma D, Liu ZH. Regulation of activin receptor-interacting protein 2 expression in mouse hepatoma Hepa-1-6 cells and its relationship with collagen type IV. *World J Gastroenterol* 2007; 13: 5501-5505 [PMID: 17907296]

14 Deli A, Kreidie F, Santifaller S, Trotter B, Seir K, Berger W, Schulhe-Herrmann R, Rodgarka-Dara C, Grusch M. Activins and activin antagonists in hepatocellular carcinoma. *World J Gastroenterol* 2008; 14: 1699-1709 [PMID: 18350601]

15 Fuji T, Fuchs BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, Lanuti M, Tanabe KK. Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. *BMJ Cancer* 2010; 10: 79 [PMID: 20618941 DOI: 10.1186/1471-2407-10-79]

16 Gold EF, Francis RJ, Zimmermann A, Mellor SL, Cranfield M, Risbridger GP, Groome NP, Wheatley AM, Fleming JS. Changes in activin and activin receptor subunit expression in rat liver during the development of CCl4-induced cirrhosis. *Moh Cell Endocrinol* 2003; 201: 143-153 [PMID: 12706302]

17 Liu HY, Wang YN, Ge J, Li N, Cui XL, Liu ZH. Localisation and role of activin receptor-interacting protein 1 in mouse brain. *J Neuroendocrinol* 2013; 25: 87-95 [PMID: 22849377 DOI: 10.1111/j.1365-2826.2012.02371.x]

18 El-Gendi SS, Monien AE, Tawfik NM, Ashamawy MM, Mohammed OA, Mostafa AK, Zakhari MM, Herdan OM. Value of serum and synovial fluid activin A and inhibin A in some rheumatic diseases. *Int J Rheum Dis* 2010; 13: 273-279 [PMID: 20704626 DOI: 10.1111/j.1756-185X.2010.01532.x]

19 Zhang YQ, Resta S, Jung B, Barrett KE, Sarvetnick N. Up-regulation of activin signaling in experimental colitis. *Am J Physiol Gastrointest Liver Physiol* 2009; 297: G676-G780 [PMID: 19643954 DOI: 10.1152/ajpgi.00631.2008]

20 Michel U, Ebert S, Phillips D, Nau R. Serum concentrations of activin and follistatin are elevated and run in parallel in patients with septicemia. *Eur J Endocrinol* 2003; 148: 559-564 [PMID: 12720540]

21 Allendorph GP, Vale WW, Choe S. Structure of the ternary complex of a TGF-beta superfamily member. *Proc Natl Acad Sci U S A* 2006; 103: 7643-7648 [PMID: 16672363]

22 Tsuchida K, Nakatani M, Matsuizaki T, Yamakawa N, Liu Z, Bao Y, Arai KY, Murakami T, Takehara Y, Kuriakisa A, Sugino H. Novel factors in regulation of activin signaling. *Mol Cell Endocrinol* 2004; 225: 1-8 [PMID: 15451561]

23 Liu ZH, Tsuchida K, Matsuizaki T, Bao YL, Kuriakisa A, Sugino H. Characterization of isoforms of activin receptor-interacting protein 2 that augment activin signaling. *J Endocrinol* 2006; 199: 409-421 [PMID: 16648306]

24 Kim HY, Kim JK, Choi JH, Jung YJ, Oh WY, Kim DC, Lee HS, Kim YS, Kang SS, Lee SH, Lee SM. Hepatoprotective effect of pinoresinol on carbon tetrachloride-induced hepatic damage in mice. *J Pharmacol Sci* 2010; 112: 105-112 [PMID: 20907970]

25 Allman M, Gaskin L, Rivera CA. C4H-induced hepatic injury in mice fed a Western diet is associated with blunted healing. *J Gastroenterol Hepatol* 2010; 25: 635-643 [PMID: 20570333 DOI: 10.1111/j.1440-1746.2009.06112.x]

26 Ma X, Xu L, Wang S, Chen H, Xu J, Li X, Ning G. Loss of steroid receptor co-activator-3 attenuates carbon tetrachloride-induced murine hepatic injury and fibrosis. *Lab Invest* 2009; 89: 903-914 [PMID: 19488034 DOI: 10.1038/labinvest]

27 Patella S, Phillips DJ, Tchongue J, de Krefter DM, Sievert W. Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. *Am J Physiol Gastrointest Liver Physiol* 2006; 290: G137-G144 [PMID: 16123203]

P-Reviewers Ding WX, Ohkohuchi N, Shimizu Y, Tarantino G S-Editor Gou SX L-Editor A E-Editor Xiong L